65,437 trials
B-cell Malignancies · Colorectal Cancer (CRC) · Head and Neck Cancer
Primary: Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Alcohol Use Disorder (AUD)
Primary: Visual Analogue Scale (VAS) of Craving Severity: 2 Arms — 2.38; 1.44 score on a scale
Healthy
Primary: Part A: Area Under the Concentration-time Curve of Alteplase in Plasma Over the Time Interval From 0 up to the Last Quantifiable Data Point (AUC0-tz)
Coronary Artery Disease
Primary: Maximal Platelet Aggregation (MPA%) by Light Transmittance Aggregometry (LTA) — 27; 53; 20; 4 percentage of MPA
Pneumococcal Disease
Primary: Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination — 37.7; 39.1; 37.2; 15.1 Percentage of participants
Musculoskeletal Pain
Primary: Low Back Pain Rating Visual Analog Scale — 44.5; 32.1; 38.2; 34.1 units on a scale
Heart Failure
Primary: Change in Peak Rate of Oxygen (VO2) — 0.85; 0.70 ml/min/kg — p=0.770
Alcohol Dependence · Post-Traumatic Stress Disorder (PTSD)
Primary: Visual Analogue Scale of Craving (VASC) Baseline no Script — 1.29; 0.60 units on a scale
Smiling · Botulinum Toxins, Type A
Primary: Anterior Gingival Exposure (GE) 4 Weeks Post-injection — 3.6; 3.0 mm
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma · Metastatic Malignant Solid Neoplasm · Metastatic Primary Peritoneal Serous Adenocarcinoma
Primary: Maximum Tolerated Dose (MTD) of Olaparib Administered in Combination With Onalespib — 300; 200 mg
Overweight and Obesity · Physical Activity · Weight Change, Body
Primary: Gestational Weight Change — 6.9; 8.8 kilograms
Giant Cell Arteritis
Primary: Percentage of Participants in Sustained Remission Until Week 28 — 19; 6 Participants
Infraorbital Hollows
Primary: Responder Rate Based on the Blinded Evaluator's Live Assessment of the Galderma Infraorbital Hollows Scale (GIHS) — 87.4; 17.7 Percentage of participants — p=<0.001
Alcohol Consumption
Primary: Change in Bile Salt Metabolism (C4 )Levels to Determine Effect of FXR
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8 · Stage IVA Lung Cancer AJCC v8
Primary: Overall Survival (OS) — 11.6; 14.5 months — p=0.05